Table 3.
Prevalence of potential inappropriate/teratogen prescriptions during pregnancy according to trimesters at risk and ATC groups
| Potential inappropriate drugs | ATC | Trimester at risk | Na | % |
| Total | 44,303 | 23.33 | ||
| Progestogens | G03D | 1-2 | 38,146 | 20.09 |
| Glucocorticoids for systemic use | H02AB | 1 | 4458 | 2.35 |
| Propionic acid derivates (Ibuprofen, Naproxen, Ketoprofen) | M01AE01-03 | 1-3 | 2495 | 1.31 |
| Anti-inflammatory and antirheumatic | M01AX | 1-3 | 2203 | 1.16 |
| Acetic acid derivatives and related substances (excluding Indomethacin) | M01AB (exc M01AB01) | 1-3 | 1461 | 0.77 |
| Oxicams | M01 AC | 1-3 | 200 | 0.11 |
| Bile acid sequestrants | C10AC | 1-3 | 191 | 0.10 |
| Coxib | M01AH | 1-2 | 40 | 0.02 |
| Antigonadotropins and similar agents | G03XA | 1-2 | 8 | 0.00 |
| Indomethacin | M01AB01 | 1-2 | 8 | 0.00 |
| Ezetimibe | C10AX09 | 1-3 | 1 | 0.00 |
| Nicotinic acid and its derivatives | C10AD | 1-3 | 0 | 0.00 |
| Known or potential teratogen drugs | ATC | Trimester at risk | Na | % |
| Total | 1420 | 0.78 | ||
| ACE-inhibitors, ARBs or combinations | C09 | 2-3 | 508 | 0.27 |
| HMG-CoA reductase inhibitors (statins) | C10AA,C10B | 1-3 | 297 | 0.16 |
| Barbiturates and derivatives | N03AA | 1-3 | 199 | 0.10 |
| Fatty acid derivatives | N03AG | 1-3 | 177 | 0.09 |
| Benzodiazepine derivatives | N03AE | 1-3 | 132 | 0.07 |
| Tetracycline | J01AA | 3 | 91 | 0.05 |
| Imidazole and its derivatives (Thiamazole) | H03BB02 | 1 | 48 | 0.03 |
| Triazole and its derivatives (Fluconazole) | J02AC01 | 1 | 16 | 0.01 |
| Lithium | N05AN01 | 1-3 | 16 | 0.01 |
| Vitamin K antagonists | B01AA | 1-3 | 13 | 0.01 |
| Anti-arrhythmic drugs class III (Amiodarone) | C01BD01 | 1-3 | 9 | 0.00 |
| Retinoids for acne treatment | D10BA01 | 1 | 4 | 0.00 |
| Penicillamine and similar agents | M01CC | 1-3 | 3 | 0.00 |
| Retinoids for psoriasis treatment | D05BB | 1-3 | 2 | 0.00 |
awomen with at least one prescription